Cancer drug interaction study halted after just one patient

NCT ID NCT06929260

Terminated Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This early-stage study aimed to see how the experimental drug ceralasertib affects the way the body processes three other drugs (Drug X, Y, and Z) in people with advanced solid tumours. Only one person was enrolled before the study was terminated, so no useful information was gathered. The trial was designed to measure drug levels in the blood, not to test whether ceralasertib treats cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ceralasertib (AZD6738)
What this could lead to: If successful, this could help doctors understand how ceralasertib interacts with other drugs, guiding safer combination treatments for advanced cancers.
What could go wrong: This was a very early, small study (only 1 participant) and was terminated, so no meaningful conclusions can be drawn. It does not test whether ceralasertib works against cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOUR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer endometrial cancer neoplasm non-small cell lung carcinoma ovarian cancer prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOURS

Contacts and locations

Locations

Research Site

Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.